Evidence map›Paper›PMID 28005993›Full record

ArticlePloS one2016

Decreased Peak Expiratory Flow Associated with Muscle Fiber-Type Switching in Spinal and Bulbar Muscular Atrophy.

Shinichiro Yamada, Atsushi Hashizume, Yasuhiro Hijikata, Tomonori Inagaki, Keisuke Suzuki, Naohide Kondo, Kaori Kawai, Seiya Noda, Hirotaka Nakanishi, Haruhiko Banno and 6 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Molecular Mechanisms and Therapeutics for SBMA/Kennedy's Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2019
    Review
  16. Article
  17. Article
  18. Beyond motor neurons: expanding the clinical spectrum in Kennedy's disease.Journal of neurology, neurosurgery, and psychiatry · 2018
    Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Shinichiro YamadaDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Atsushi HashizumeDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yasuhiro HijikataDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Tomonori InagakiDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Keisuke SuzukiInnovation Center for Clinical Research, National Center for Geriatrics and Gerontology, Obu, Japan.
Naohide KondoDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kaori KawaiDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Seiya NodaDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hirotaka NakanishiDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Haruhiko BannoDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Akihiro HirakawaBiostatistics Section, Center for Advanced Medicine and Clinical Research, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Haruki KoikeDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Katherine HalievskiNeuroscience Program, Michigan State University, East Lansing, Michigan, United States of America.
Cynthia L JordanNeuroscience Program, Michigan State University, East Lansing, Michigan, United States of America.
Masahisa KatsunoDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Gen SobueDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nagoya University · JPMichigan State University · USNational Center for Geriatrics and Gerontology · JP

Funding

Androgen Targets in a Simple Behavioral SystemR01NS045195 · NINDS · MICHIGAN STATE UNIVERSITY · PI JORDAN, CYNTHIA L · 2003 to 2019
$5.3M
NINDS NIH HHS R01 NS045195
6 · The paper itself

Abstract

The aim of this study was to characterize the respiratory function profile of subjects with spinal and bulbar muscular atrophy (SBMA), and to explore the underlying pathological mechanism by comparing the clinical and biochemical indices of this disease with those of amyotrophic lateral sclerosis (ALS). We enrolled male subjects with SBMA (n = 40) and ALS (n = 25) along with 15 healthy control subjects, and assessed their respiratory function, motor function, and muscle strength. Predicted values of peak expiratory flow (%PEF) and forced vital capacity were decreased in subjects with SBMA compared with controls. In SBMA, both values were strongly correlated with the trunk subscores of the motor function tests and showed deterioration relative to disease duration. Compared with activities of daily living (ADL)-matched ALS subjects, %PEF, tongue pressure, and grip power were substantially decreased in subjects with SBMA. Both immunofluorescence and RT-PCR demonstrated a selective decrease in the expression levels of the genes encoding the myosin heavy chains specific to fast-twitch fibers in SBMA subjects. The mRNA levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha and peroxisome proliferator-activated receptor delta were up-regulated in SBMA compared with ALS and controls. In conclusion, %PEF is a disease-specific respiratory marker for the severity and progression of SBMA. Explosive muscle strength, including %PEF, was selectively affected in subjects with SBMA and was associated with activation of the mitochondrial biogenesis-related molecular pathway in skeletal muscles.

Indexed as

AdultAgedAged, 80 and overAmyotrophic Lateral SclerosisDisease ProgressionHumansMaleMiddle AgedMuscle Fibers, SkeletalMuscle StrengthMuscular Atrophy, SpinalMuscular Disorders, AtrophicPeak Expiratory Flow RatePeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPPAR deltaRespiratory Function TestsPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPPAR deltaRNA, Messenger

Identifiers

PMID28005993
PMCPMC5179045
OpenAlexW2569611865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.